The Dynamics of Human Cytomegalovirus Replication in Vivo

Cytomegalovirus (CMV) is generally described as a slowly replicating virus. During studies of immunocompromised patients, we observed rapid changes in the quantity of CMV DNA present in serial blood samples by quantitative-competitive polymerase chain reaction commensurate with a doubling time of <2 d. To further investigate the dynamics of replication in vivo, patients in three distinct situations were studied in detail: (a) those receiving intravenous ganciclovir; (b) those in whom ganciclovir-resistant strains appeared during long-term therapy; and (c) those in whom ganciclovir-resistant strains disappeared with alternative drug therapy. In all cases, it was possible to provide accurate estimates of the doubling time of CMV and its half-life of disappearance after antiviral chemotherapy. The results from all three approaches demonstrated that the doubling time/half-life of CMV in blood is ∼1 d when frequent samples are collected. These results show that CMV DNA replication in vivo is a highly dynamic process. We conclude that the reputation of CMV as a slowly replicating virus based on the time taken to produce cytopathic effects in vitro is unwarranted. These findings have implications for the potency, dose, and duration of antiviral chemotherapy needed for the effective treatment of this important human pathogen.

[1]  J. Cherrington,et al.  Clinical uses of cidofovir , 1997, Reviews in medical virology.

[2]  P. Griffiths,et al.  Use of the polymerase chain reaction to analyse sequence variation within a major neutralizing epitope of glycoprotein B (gp58) in clinical isolates of human cytomegalovirus. , 1991, The Journal of general virology.

[3]  M. Miller,et al.  Molecular epidemiology of cytomegalovirus infections associated with bone marrow transplantation. , 1985, Annals of internal medicine.

[4]  C. Sabin,et al.  Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation , 1997, Journal of medical virology.

[5]  S. Riddell,et al.  T cell therapy of human CMV and EBV infection in immunocompromised hosts , 1997, Reviews in medical virology.

[6]  M A Nowak,et al.  Human immunodeficiency virus drug therapy and virus load , 1997, Journal of virology.

[7]  M A Nowak,et al.  Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Walker-Smith,et al.  SMALL-INTESTINAL HISTOLOGY IN CŒLIAC DISEASE , 1975, The Lancet.

[9]  Angela R. McLean,et al.  Zidovudine and HIV: Mathematical models of within‐host population dynamics , 1995 .

[10]  S. Spector,et al.  Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients. , 1998, The Journal of clinical investigation.

[11]  M A Nowak,et al.  Pre-existence and emergence of drug resistance in HIV-1 infection. , 1997, Proceedings. Biological sciences.

[12]  C. Crumpacker Drug therapy : Ganciclovir , 1996 .

[13]  C. Sabin,et al.  Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease , 1998, Bone Marrow Transplantation.

[14]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[15]  C. Sabin,et al.  The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency virus disease. AIDS Clinical Trials Group Protocol 204/Glaxo Wellcome 123-014 International CMV Prophylaxis Study Group. , 1998, The Journal of infectious diseases.

[16]  C. Sabin,et al.  Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival , 1996, AIDS.

[17]  M A Nowak,et al.  Viral dynamics in hepatitis B virus infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[19]  S. Chou,et al.  Reactivation and recombination of multiple cytomegalovirus strains from individual organ donors. , 1989, The Journal of infectious diseases.

[20]  Martin A. Nowak,et al.  Viral dynamics in human immunodeficiency virus type 1 infection , 1995, Nature.

[21]  C. Sabin,et al.  Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV‐positive patients at high risk of CMV disease , 1997, AIDS.

[22]  A S Perelson,et al.  Human immunodeficiency virus fitness in vivo: calculations based on a single zidovudine resistance mutation at codon 215 of reverse transcriptase , 1996, Journal of virology.

[23]  Wilmot THE CHARTER OF THE ROYAL COLLEGE OF SURGEONS IN LONDON. , 1824 .

[24]  K. Fish,et al.  Reactivation of Latent Human Cytomegalovirus by Allogeneic Stimulation of Blood Cells from Healthy Donors , 1997, Cell.

[25]  C. Sabin,et al.  Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. , 1997, The Journal of infectious diseases.

[26]  P. Griffiths,et al.  Development of a point mutation assay for the detection of human cytomegalovirus UL97 mutations associated with ganciclovir resistance. , 1997, Journal of virological methods.

[27]  S. Chou,et al.  Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. , 1995, The Journal of infectious diseases.

[28]  D. Pillay Book review. Antiviral Drug Resistance Ed. by Douglas D. Richman, John Wiley & Sons, Chichester, 1996. , 1998 .

[29]  藤井 良知 Cytomegalovirus , 1966, Definitions.

[30]  P. Griffiths,et al.  Quantification of human cytomegalovirus DNA using the polymerase chain reaction. , 1992, The Journal of general virology.

[31]  P. Griffiths,et al.  SYMPTOMATIC CYTOMEGALOVIRUS INFECTION IN SEROPOSITIVE KIDNEY RECIPIENTS: REINFECTION WITH DONOR VIRUS RATHER THAN REACTIVATION OF RECIPIENT VIRUS , 1988, The Lancet.

[32]  C. Sabin,et al.  Cytomegalovirus polymerase chain reaction viraemia in patients receiving ganciclovir maintenance therapy for retinitis , 1998, AIDS.